A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Clinical trial NCT02505568 · COMPLETED
Trial details
- NCT number
- NCT02505568
- Sponsor
- Janssen Korea, Ltd., Korea
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-22
- Primary completion
- 2018-07-13
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.